Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.

Journal of neurology·2016
Same author

[Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2002
Same author

What's bad for the gander...women and sudden cardiac death.

Heart (British Cardiac Society)·2002
Same author

Task Force on Sudden Cardiac Death, European Society of Cardiology.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2002
Same author

Localization of the origin of arrhythmias for ablation: from Electrocardiography to advanced endocardial mapping systems.

Journal of cardiovascular electrophysiology·2002
Same author

President's page: guidelines: tools for building better patient care.

Journal of the American College of Cardiology·2001

相关实验视频

Updated: Jul 8, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

抑制Na(+) /H(+) 交换器延迟了快速节奏诱导的心房收缩功能障碍的发展.

G T Altemose1, D P Zipes, J Weksler

  • 1Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis 46202, USA.

Circulation
|February 7, 2001
PubMed
概括

使用HOE642阻塞Na(+) /H(+) 交换器 (NHE),可显著地保护心率快速期间的左心房机械功能,减轻心房动后的心房麻木.

科学领域:

  • 心脏病学 心脏病学
  • 电子生理学 电子生理学
  • 心脏生理学 心脏生理学

背景情况:

  • 在心房动后,心房机械麻醉可能会持续.
  • 与快速率相关的心房收缩功能障碍的机制尚未完全理解.
  • 潜在的机制包括缺血,pH值变化和过载.

研究的目的:

  • 调查Na(+) /H(+) 交换器 (NHE) 阻塞对由心率加快引起的心房收缩功能障碍的影响.
  • 为了测试NHE阻塞在快速节奏过程中改变心房机械功能的假设.

主要方法:

  • 23只狗接受了5个小时的快速右心房节奏.
  • 动物接受了NHE抑制剂 (HOE642),盐水 (对照) 或尼菲迪平.
  • 使用声微米,食管横断心声学和血液动力学监测来评估左心房功能.

主要成果:

  • 与对照组和nifedipine组相比,NHE抑制显著降低了左心房分数缩短的下降.
  • 左心房附属体收缩速度 (LAACV) 在NHE抑制剂组与对照组相比显著保持.
  • 与尼菲迪平组相比,LAACV在NHE抑制剂组中也得到了显著的保存.

结论:

更多相关视频

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

相关实验视频

Last Updated: Jul 8, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

  • 用HOE642治疗有效地减轻了由快速心房率引起的左心房机械功能的下降.
  • 在快速节奏过程中,NHE阻塞对心房收缩功能产生保护作用.